Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2008

 
 
 

Ceftobiprole  

  • Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2008; 52(9): 3418-3423.
  • Anderson SD, Gums JG. Ceftobiprole: An extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother. 2008; 42(6): 806-816.
  • Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52(6): 2089-2096.
  • Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2008; 65(16): 1545-1551.
  • Chung M, Antignac A, Kim C, Tomasz A. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother. 2008; 52(8): 2709-2717.
  • Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008; 52(10): 3492-3496.
  • Del Pozo JL, Patel R. Ceftobiprole medocaril: A new generation β-lactam. Drugs Today. 2008; 44(11): 801-825.
  • Deresinski SC. Ceftobiprole: Breaking therapeutic dogmas of the β-lactam class. Diagn Microbiol Infect Dis. 2008; 61(1): 82-85.
  • Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: Evidence from 2 clinical trials. Diagn Microbiol Infect Dis. 2008; 61(1): 103-109.
  • Dixon T, Eiland III EH. Ceftobiprole: A novel broad-spectrum antiinfective. J Pharm Technol. 2008; 24(1): 22-27.
  • Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis. 2008; 61(1): 86-95.
  • Heinzl S. Ceftobiprole: Good effect in patients with skin and soft tissue infections. Krankenhauspharmazie. 2008; 29(7): 320-322.
  • Kisgen J, Whitney D. Ceftobiprole, a broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). P&T. 2008; 33(11): 631-641.
  • Kontou P, Kuti JL, Nicolau DP. Ceftobiprole: The first anti-MRSA cephalosporin antibiotic. Formulary 2008; 43(2): 66-78.
  • Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother. 2008; 52(7): 2389-2394.
  • Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52(8): 2974-2976.
  • Lin G, Appelbaum PC. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn Microbiol Infect Dis. 2008; 60(2): 233-235.
  • Liu Y-D, Wang H, Du N, Sun H-L, Xu Y-C, Yang Q-W, Chen M-J, Xie X-L. In vitro activities of linezolid, tigecycline, daptomycin, ceftobiprole and other antimicrobial agents against methicillin-resistant Staphylococcus aureus. Chin J Infect Chemother. 2008; 8(1): 10-14.
  • Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis. 2008; 61(1): 96-102.
  • Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008; 47(1): 21-33.
  • Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008; 46(5): 647-655.
  • Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008; 52(1): 37-44.
  • Oberpichler-Schwenk H. Ceftobiprol: A new cephalosporin with broad spectrum. Arzneimitteltherapie 2008; 26(3): 113-4.
  • Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother. 2008; 61(3): 595-602.
  • Soriano F. New antibiotics against Gram-positive microorganisms: Linezolid, tigecycline, daptomycin, dalbavancin, telavancin, ceftobiprole. Enferm Infecc Microbiol Clin. 2008; 26(2): 13-20.
  • Srinivasan V, McGowan Jr JE, McAllister S, Tenover FC. In vitro activity of ceftobiprole against coagulase-negative staphylococci isolated in the USA. Int J Antimicrob Agents 2008; 31(3): 294-296.
  • Thamlikitkul V, Trakulsomboon S. In vitro activity of ceftobiprole against Burkholderia pseudomallei. J Antimicrob Chemother. 2008; 61(2): 460-461.
  • Tomillero A, Moral MA. Gateways to clinical trials. December 2008. Methods Find Exp Clin Pharmacol. 2008; 30(10): 761-782.
  • Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. J Antimicrob Chemother. 2008; 62(1): 206-208.
  • Wang H, Liu Y, Sun H, Xu Y, Xie X, Chen M. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China. Diagn Microbiol Infect Dis. 2008; 62(2): 226-229.
  • Widmer AF. Ceftobiprole: A new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008; 46(5): 656-658.
  • Yin L-Y, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52(5): 1618-1622.
  • Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.Ceftobiprole: A review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol. 2008; 9(4): 245-254.

 

48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008, Washington, DC, United States of America

  • A-036 / Efficacy of ceftobiprole against Streptococcus pneumoniae in a murine lower respiratory tract infection model. Hilliard JJ, Melton J, Flamm RK, Bush K.
  • A-037 / Effects of ceftobiprole and vancomycin combinations in vitro and in vivo against Staphylococcus aureus. Hilliard JJ, Foleno B, Wira E, Melton J, Flamm RK, Bush K.
  • A-1881 / Pharmacokinetics of ceftobiprole (BPR) in patients with ventilator-associated pneumonia (VAP). Kimko H, Murthy B, Balis D, Strauss R, Habucky K, Noel G.
  • A-1892 / Soft-tissue penetration of ceftobiprole following single-dose administration in healthy adults. Barbour A, Murthy B, Schmidt S, Sabarinath S, Skee D, Tian H, Desai-Kreiger D,  Balis D, Grant M, Seubert C, Derendorf H.
  • A-1896 / An open-label pharmacokinetic study of ceftobiprole in healthy subjects and subjects with end-stage renal disease receiving hemodialysis. Murthy B, Skee D, Vaccaro N, Murphy J, Ariyawansa J, Desai-Kreiger D, Balis D.
  • B-057 / Ceftobiprole is superior to ceftriaxone combined with vancomycin against a
    penicillin-resistant Streptococcus strain in experimental meningitis. Cottagnoud M, Acosta F, Egermann U, Gerber P, Stucki A, Cottagnoud P.
  • C1-153 / Ceftobiprole activity tested against North American Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. in 2005-2007. Fritsche TR, Sader HS,  Janechek M, Jones RN.
  • C1-154 / Mechanisms of ceftobiprole and ceftazidime resistance development in Gram-negative clinical isolates from cSSSI subjects. Queenan AM, Shang W, Crespo-Carbone S, Baum EZ, Bush K.
  • C1-155 / In-vitro activity of ceftobiprole against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals. Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG.
  • C1-156 / Common sources of S. aureus infection in the US and prevalence of MRSA; longitudinal analysis of ceftobiprole activity against S. aureus from prevalent specimen sources. Evangelista AT, Yee YC, Torres MK, Brown NP, Pillar CM, Sahm DF, Thornsberry C.
  • C1-157 / In-vitro antibacterial activity of a new β-lactam: ceftobiprole (BPR) against Haemophilus influenzae. Lascols C, Soussy CJ, Dabernat H.
  • C1-158 / MexXY expression in Pseudomonas aeruginosa (PsA) and susceptibility to
    cephalosporins, including ceftobiprole. Baum EZ, Crespo-Carbone SM, Foleno BD, Wira E, He W, Morrow B.
  • C1-159 / Ceftobiprole activity against baseline pathogens from recent pneumonia trials. Amsler K, Jacobs M, Sahm D, Bajaksouzian S, Windau A, Pillar C, Torres M, Bush K.
  • C1-164 / Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae with varying penicillin susceptibilities. Davies TA, Flamm RK, Bush K.
  • C1-165 / In vitro selection and characterization of cephalosporin-resistant mutants in P. aeruginosa. Queenan AM, Shang W, Bush K.
  • C1-193 / In-vitro activity of ceftobiprole against 5435 pathogens obtained from patients in Canadian hospitals: CANWARD 2007. Zhanel GG, DeCorby M, Nichol K, Hoban DJ, Karlowsky JA.
  • C1-194 / In-vitro antibacterial activity of ceftobiprole (BPR) against hospital isolates proposal for zone diameter breakpoints: a French multicenter study. Lascols C, Drugeon HB,  Kitzis MD, Leclercq R, Merens A, Muller-Serieys C, Reverdy ME, Roussel-Delvallez M, Bremont S,  Marmiesse M, Soussy CJ.
  • C1-1079 / Genetic relatedness among United States methicillin-susceptible and -resistant Staphylococcus aureus isolates from ceftobiprole clinical trials. Davies TA, Zhang W, Shang W, Amsler K, Flamm RK, Bush K.
  • D-2230 / A comparison of ceftobiprole and ceftazidime MICs by European methods against 121 Gram-positive and Gram-negative organisms. Koeth LM, DiFranco JM, Poeschel A, Rodloff A, Smyth R, Kahlmeter G, Warner M, Livermore D, Lascols C, Soussy CJ.
  • D-2231 / A comparison of broth microdilution and agar dilution methods for in-vitro testing of ceftobiprole. Lascols C, Moubareck C, Drugeon H, Leclercq R, Soussy CJ.
  • K-486 / Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. Noel GJ, Strauss RS, Shah A, Bagchi P, BAP00248/307 Study Group.

 

ATS International Conference, May 2008, Toronto, Canada

  • C-16 / Efficacy of ceftobiprole compared to ceftriaxone +/- linezolid for the treatment of subjects hospitalized with community-acquired pneumonia. Nicholson SC, Strauss RS, Michiels B, Noel GJ. 
  • C-17 / Efficacy of ceftobiprole for the treatment of severely ill patients hospitalized with community-acquired pneumonia. Nicholson SC, Strauss RS, Michiels B, Noel GJ.

 

18th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2008, Barcelona, Spain

  • P-578 / Antimicrobial activity of ceftobiprole tested against leading European bacterial pathogens: results from an international surveillance program (2005-2006). Fritsche TR, Sader HS, Janechek M, Jones RN.
  • P-613 / In-vitro activity of ceftobiprole against select Gram-positive and Gram-negative pathogens isolated from Europe in 2006-2007. Torres MK, Draghi DC, Brown NP, Thornsberry C, Sahm DF, Pillar CM.
  • P-1428 / Genetic relatedness among European methicillin-susceptible and -resistant Staphylococcus aureus isolates from ceftobiprole clinical trials. Davies TA, Shang W, Amsler K, Flamm RK, Bush K.
  • P-1933 / Ceftobiprole is superior to cefepime against a Klebsiella pneumoniae strain in experimental meningitis. Cottagnoud M, Acosta F, Gerber P, Stucki A, Cottagnoud PH.
 

Isavuconazole

  • Guinea J, Bouza E. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol. 2008; 3(6): 603-615.
  • Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and flusconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008; 52(4): 1396-1400.
  • Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008; 52(11): 4211.
  • Illnait-Zaragozi M-T, Martínez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother. 2008; 52(4): 1580-1582.
  • Thompson III GR, Fothergill AW, Wiederhold NP, Vallor AC, Wickes BL, Patterson TF. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother. 2008; 52(8): 2959-2961.
 

48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008, Washington, DC, United States of America

  • A-007 / Pharmacokinetics of isavuconazole in liver impairment. Preliminary data. Schmitt-Hoffmann A, Roos B, Peterfaí É, Edwards D, Spickermann J, Heep M.
  • A-008 / No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. Schmitt-Hoffmann A, Roos B, Roehrle M, Spickermann J, Schoetzau A, Simmen U, Heep M.
  • M-1525 / Antifungal activity of old and new antifungal agents against 94 clinical isolates of Cryptococcus neoformans var. grubii and var. neoformans: Are there differences between the varieties? Guinea J.; Peláez T.; Tahoune H., Recio S., Torres-Narbona M., Hagen F., Boekhout T., Bouza E.
  • M-1526 / The in vitro activity of isavuconazole against Aspergillus species and zygomycetes according to EUCAST methodology. Perkhofer S, Lechner V, Lass-Flörl C.
  • M-1531 / Antifungal susceptibility among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Thompson III GR, Fothergill AW, Vallor AC, Wiederhold NP, Wickes BL, Patterson TF.
  • M-2137 / Pharmacokinetics, safety and tolerability results from a dose escalation study of isavuconazole in neutropenic patients. Cornely OA, Böhme A, Reichert D, Heep M, Roos B, Schmitt-Hoffmann A, Ullmann AJ.
  • M-2140 / Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole (BAL8557): mathematical modeling, the importance of tissue concentrations and the impact of immune status on the antifungal effect. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW.

 

18th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2008, Barcelona, Spain

  • P-1914 / Efficacy of isavuconazole, voriconazole and fluconazole in neutropenic murine models of disseminated Candida tropicalis (CT) and Candida krusei (CK). Majithiya JB, Sharp A, Parmar A, Denning DW, Warn PA.
  • P-1915 / Correlation of in vitro MIC and MFC against isavuconazole, voriconazole and amphotericin B of Aspergillus with in vivo outcome in mice with disseminated aspergillosis. Majithiya JB, Sharp A, Parmar A, Denning DW, Warn PA.
  • P-2176 / Comparison between Isavuconazole (ISA) and other azoles against characterized clinical isolates and yeast model systems. Sanglard D, Ischer F, Coste A, Ferrari S.
  • P-2177 / In vitro post antibiotic effect of isavuconazole, voriconazole and amphotericin against a strain of C. albicans with concentration dependent pharmacokinetics in a murine model and susceptibility of strains from mouse kidneys post infection. Warn PA, Sharp A, Majithiya JB, Parmar A, Denning DW.

 

Research

48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008, Washington, DC, United States of America

  • F1-1165 / BAL30072, a siderophore monobactam, with extended activity against multidrug- resistant (MDR) Acinetobacter baumannii. Hujer AM, Hujer KM, Desabre E, Endimiani A, Page MGP, Bonomo RA.
  • F1-1166 / Efficacy of BAL30376, a new monobactam beta lactamase inhibitors combination against Pseudomonas aeruginosa (PA). Hermesh O, Page M, Schmitt-Hoffmann A, Carmeli Y, Navon-Venezia S.
  • F1-1173 / Interaction of BAL30072 with penicillin-binding proteins of Gram-negative bacteria. Dantier C, Desabre E, Page MGP.
  • F1-1174 / Thermodynamic studies of the inhibition of AmpC beta-lactamase by BAL30072 and other monobactams. Danel F, Dantier C, Richalet F, Desarbre E, Page MGP.
  • F1-1175 / In vitro activity of the siderophore monobactam BAL30072 against multiresistant non-fermenting Gram-negative pathogens. Hofer B, Müller C, Desarbre E, Page MGP.
  • F1-3936 / The comparative activity of the dihydrofolate reductase inhibitors BAL0030543, BAL0030544 and BAL0030545 against clinical strains of Gram-positive pathogens from the UK. Bowker KW, MacGowan AP.
  • F1-3937 / Antistaphylococcal activities of dihydrophthalazine antifolates, a family of novel antibacterial drugs, by time-kill analysis. Lin G, Ednie LM, Shapiro S, Caspers P, Gaucher B, Appelbaum PC.
  • F1-3938 / Dihydrophthalazine antifolates, a family of novel antibacterial drugs: in vitro activities against coagulase-negative staphylococci. Ednie LM, Smith KA, Caspers P, Gaucher B, Shapiro S, Appelbaum PC.
  • F1-3939 / Proclivity of dihydrophthalazine antifolates and comparators to select for staphylococcal resistance. Clark C, Kosowska-Shick K, Caspers P, Gaucher B, Shapiro S, Appelbaum PC.
 
Info